Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C

John G. Mchutchison, Stuart C. Gordon, Eugene R. Schiff, Mitchell L. Shiffman, William M. Lee, Vinod K. Rustgi, Zachary D. Goodman, Mei Hsiu Ling, Susannah Cort, Janice K. Albrecht

Research output: Contribution to journalArticle

3262 Citations (Scopus)

Abstract

Background. Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods. We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results. The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001) for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy. Conclusions. In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone.

Original languageEnglish (US)
Pages (from-to)1485-1492
Number of pages8
JournalNew England Journal of Medicine
Volume339
Issue number21
DOIs
StatePublished - Nov 19 1998

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Interferons
Therapeutics
Hepacivirus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mchutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., ... Albrecht, J. K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339(21), 1485-1492. https://doi.org/10.1056/NEJM199811193392101

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. / Mchutchison, John G.; Gordon, Stuart C.; Schiff, Eugene R.; Shiffman, Mitchell L.; Lee, William M.; Rustgi, Vinod K.; Goodman, Zachary D.; Ling, Mei Hsiu; Cort, Susannah; Albrecht, Janice K.

In: New England Journal of Medicine, Vol. 339, No. 21, 19.11.1998, p. 1485-1492.

Research output: Contribution to journalArticle

Mchutchison, JG, Gordon, SC, Schiff, ER, Shiffman, ML, Lee, WM, Rustgi, VK, Goodman, ZD, Ling, MH, Cort, S & Albrecht, JK 1998, 'Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C', New England Journal of Medicine, vol. 339, no. 21, pp. 1485-1492. https://doi.org/10.1056/NEJM199811193392101
Mchutchison, John G. ; Gordon, Stuart C. ; Schiff, Eugene R. ; Shiffman, Mitchell L. ; Lee, William M. ; Rustgi, Vinod K. ; Goodman, Zachary D. ; Ling, Mei Hsiu ; Cort, Susannah ; Albrecht, Janice K. / Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. In: New England Journal of Medicine. 1998 ; Vol. 339, No. 21. pp. 1485-1492.
@article{bc09b1b077da4cab8a1e722fb8eb6a0e,
title = "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C",
abstract = "Background. Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods. We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results. The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001) for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy. Conclusions. In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone.",
author = "Mchutchison, {John G.} and Gordon, {Stuart C.} and Schiff, {Eugene R.} and Shiffman, {Mitchell L.} and Lee, {William M.} and Rustgi, {Vinod K.} and Goodman, {Zachary D.} and Ling, {Mei Hsiu} and Susannah Cort and Albrecht, {Janice K.}",
year = "1998",
month = "11",
day = "19",
doi = "10.1056/NEJM199811193392101",
language = "English (US)",
volume = "339",
pages = "1485--1492",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "21",

}

TY - JOUR

T1 - Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C

AU - Mchutchison, John G.

AU - Gordon, Stuart C.

AU - Schiff, Eugene R.

AU - Shiffman, Mitchell L.

AU - Lee, William M.

AU - Rustgi, Vinod K.

AU - Goodman, Zachary D.

AU - Ling, Mei Hsiu

AU - Cort, Susannah

AU - Albrecht, Janice K.

PY - 1998/11/19

Y1 - 1998/11/19

N2 - Background. Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods. We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results. The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001) for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy. Conclusions. In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone.

AB - Background. Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods. We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results. The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001) for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy. Conclusions. In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone.

UR - http://www.scopus.com/inward/record.url?scp=0032547938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032547938&partnerID=8YFLogxK

U2 - 10.1056/NEJM199811193392101

DO - 10.1056/NEJM199811193392101

M3 - Article

C2 - 9819446

AN - SCOPUS:0032547938

VL - 339

SP - 1485

EP - 1492

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -